ClinicalTrials.gov record
Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension
ClinicalTrials.gov ID: NCT00281580
Public ClinicalTrials.gov record NCT00281580. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Double-dummy, Placebo-controlled, 4x4 Factorial Design Trial to Evaluate Telmisartan 20, 40 and 80 mg Tablets in Combination With Amlodipine 2.5, 5 and 10 mg Capsules After Eight Weeks of Treatment in Patients With Stage I or II Hypertension, With an ABPM Sub-study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To demonstrate that Micardis and Norvasc when used together are more effective at lowering blood pre ssure.
Study identification
- NCT ID
- NCT00281580
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,461 participants
Conditions and interventions
Conditions
Interventions
- Amlodipine 5 mg Drug
- Placebo Drug
- Telmisartan 20 mg Drug
- Telmisartan 40 mg Drug
- Amlodipine 10 mg Drug
- Telmisartan 80 mg Drug
- Amlodipine 2.5 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2006 (Type not available)
- Primary completion
- Mar 2007 (Actual)
- Completion
- Not listed
- Last update posted
- Mar 27, 2014
Started 2006
United States locations
- U.S. sites
- 101
- U.S. states
- 29
- U.S. cities
- 84
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1235.1.457 Boehringer Ingelheim Investigational Site | Fairhope | Alabama | — | — |
| 1235.1.368 Boehringer Ingelheim Investigational Site | Huntsville | Alabama | — | — |
| 1235.1.389 Boehringer Ingelheim Investigational Site | Huntsville | Alabama | — | — |
| 1235.1.411 Boehringer Ingelheim Investigational Site | Huntsville | Alabama | — | — |
| 1235.1.429 Boehringer Ingelheim Investigational Site | Chandler | Arizona | — | — |
| 1235.1.420 Boehringer Ingelheim Investigational Site | Tempe | Arizona | — | — |
| 1235.1.391 Boehringer Ingelheim Investigational Site | Cudahy | California | — | — |
| 1235.1.444 Boehringer Ingelheim Investigational Site | Encinitas | California | — | — |
| 1235.1.445 Boehringer Ingelheim Investigational Site | Encino | California | — | — |
| 1235.1.357 Boehringer Ingelheim Investigational Site | Long Beach | California | — | — |
| 1235.1.465 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1235.1.441 Boehringer Ingelheim Investigational Site | Riverside | California | — | — |
| 1235.1.409 Boehringer Ingelheim Investigational Site | Sacramento | California | — | — |
| 1235.1.406 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 1235.1.414 Boehringer Ingelheim Investigational Site | Santa Ana | California | — | — |
| 1235.1.383 Boehringer Ingelheim Investigational Site | Spring Valley | California | — | — |
| 1235.1.395 Boehringer Ingelheim Investigational Site | Tustin | California | — | — |
| 1235.1.453 Boehringer Ingelheim Investigational Site | Milford | Connecticut | — | — |
| 1235.1.394 Boehringer Ingelheim Investigational Site | Newark | Delaware | — | — |
| 1235.1.354 Boehringer Ingelheim Investigational Site | Cooper City | Florida | — | — |
| 1235.1.451 Boehringer Ingelheim Investigational Site | DeLand | Florida | — | — |
| 1235.1.372 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 1235.1.396 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 1235.1.390 Boehringer Ingelheim Investigational Site | Hialeah | Florida | — | — |
| 1235.1.430 Boehringer Ingelheim Investigational Site | Kissimmee | Florida | — | — |
| 1235.1.351 Boehringer Ingelheim Investigational Site | Melbourne | Florida | — | — |
| 1235.1.398 Boehringer Ingelheim Investigational Site | Melbourne | Florida | — | — |
| 1235.1.405 Boehringer Ingelheim Investigational Site | Mirimar | Florida | — | — |
| 1235.1.352 Boehringer Ingelheim Investigational Site | Pembroke Pines | Florida | — | — |
| 1235.1.369 Boehringer Ingelheim Investigational Site | Pembroke Pines | Florida | — | — |
| 1235.1.397 Boehringer Ingelheim Investigational Site | Pembroke Pines | Florida | — | — |
| 1235.1.449 Boehringer Ingelheim Investigational Site | Pensacola | Florida | — | — |
| 1235.1.355 Boehringer Ingelheim Investigational Site | Rockledge | Florida | — | — |
| 1235.1.407 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 1235.1.380 Boehringer Ingelheim Investigational Site | Tucker | Georgia | — | — |
| 1235.1.438 Boehringer Ingelheim Investigational Site | Gurnee | Illinois | — | — |
| 1235.1.373 Boehringer Ingelheim Investigational Site | Evansville | Indiana | — | — |
| 1235.1.375 Boehringer Ingelheim Investigational Site | Evansville | Indiana | — | — |
| 1235.1.415 Boehringer Ingelheim Investigational Site | Indianapolis | Indiana | — | — |
| 1235.1.412 Boehringer Ingelheim Investigational Site | South Bend | Indiana | — | — |
| 1235.1.435 Boehringer Ingelheim Investigational Site | Arkansas City | Kansas | — | — |
| 1235.1.379 Boehringer Ingelheim Investigational Site | Lenexa | Kansas | — | — |
| 1235.1.421 Boehringer Ingelheim Investigational Site | Newtown | Kansas | — | — |
| 1235.1.356 Boehringer Ingelheim Investigational Site | Wichita | Kansas | — | — |
| 1235.1.423 Boehringer Ingelheim Investigational Site | Louisville | Kentucky | — | — |
| 1235.1.387 Boehringer Ingelheim Investigational Site | North Dartmouth | Massachusetts | — | — |
| 1235.1.424 Boehringer Ingelheim Investigational Site | Bay City | Michigan | — | — |
| 1235.1.385 Boehringer Ingelheim Investigational Site | Florissant | Missouri | — | — |
| 1235.1.452 Boehringer Ingelheim Investigational Site | Florissant | Missouri | — | — |
| 1235.1.365 Boehringer Ingelheim Investigational Site | Kansas City | Missouri | — | — |
| 1235.1.431 Boehringer Ingelheim Investigational Site | Kansas City | Missouri | — | — |
| 1235.1.454 Boehringer Ingelheim Investigational Site | Henderson | Nevada | — | — |
| 1235.1.426 Boehringer Ingelheim Investigational Site | Cherry Hill | New Jersey | — | — |
| 1235.1.434 Boehringer Ingelheim Investigational Site | Stratford | New Jersey | — | — |
| 1235.1.366 Boehringer Ingelheim Investigational Site | East Syracuse | New York | — | — |
| 1235.1.377 Boehringer Ingelheim Investigational Site | Northport | New York | — | — |
| 1235.1.427 Boehringer Ingelheim Investigational Site | Rochester | New York | — | — |
| 1235.1.381 Boehringer Ingelheim Investigational Site | Williamsville | New York | — | — |
| 1235.1.410 Boehringer Ingelheim Investigational Site | Burlington | North Carolina | — | — |
| 1235.1.400 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| 1235.1.422 Boehringer Ingelheim Investigational Site | Greenboro | North Carolina | — | — |
| 1235.1.403 Boehringer Ingelheim Investigational Site | Lenior | North Carolina | — | — |
| 1235.1.376 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | — | — |
| 1235.1.392 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | — | — |
| 1235.1.384 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 1235.1.458 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 1235.1.374 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 1235.1.446 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 1235.1.413 Boehringer Ingelheim Investigational Site | Marion | Ohio | — | — |
| 1235.1.359 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 1235.1.361 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 1235.1.436 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 1235.1.448 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 1235.1.386 Boehringer Ingelheim Investigational Site | Tulsa | Oklahoma | — | — |
| 1235.1.439 Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| 1235.1.440 Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| 1235.1.408 Boehringer Ingelheim Investigational Site | Erie | Pennsylvania | — | — |
| 1235.1.404 Boehringer Ingelheim Investigational Site | Lansdale | Pennsylvania | — | — |
| 1235.1.428 Boehringer Ingelheim Investigational Site | Penndel | Pennsylvania | — | — |
| 1235.1.370 Boehringer Ingelheim Investigational Site | East Providence | Rhode Island | — | — |
| 1235.1.433 Boehringer Ingelheim Investigational Site | Beaufort | South Carolina | — | — |
| 1235.1.462 Boehringer Ingelheim Investigational Site | Union | South Carolina | — | — |
| 1235.1.417 Boehringer Ingelheim Investigational Site | Cordova | Tennessee | — | — |
| 1235.1.459 Boehringer Ingelheim Investigational Site | Jackson | Tennessee | — | — |
| 1235.1.363 Boehringer Ingelheim Investigational Site | New Tazewell | Tennessee | — | — |
| 1235.1.382 Boehringer Ingelheim Investigational Site | Selmer | Tennessee | — | — |
| 1235.1.442 Boehringer Ingelheim Investigational Site | Austin | Texas | — | — |
| 1235.1.399 Boehringer Ingelheim Investigational Site | Carrollton | Texas | — | — |
| 1235.1.460 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1235.1.443 Boehringer Ingelheim Investigational Site | Georgetown | Texas | — | — |
| 1235.1.416 Boehringer Ingelheim Investigational Site | Killeen | Texas | — | — |
| 1235.1.402 Boehringer Ingelheim Investigational Site | Lake Jackson | Texas | — | — |
| 1235.1.432 Boehringer Ingelheim Investigational Site | McKinney | Texas | — | — |
| 1235.1.456 Boehringer Ingelheim Investigational Site | Odessa | Texas | — | — |
| 1235.1.418 Boehringer Ingelheim Investigational Site | Plano | Texas | — | — |
| 1235.1.455 Boehringer Ingelheim Investigational Site | Waco | Texas | — | — |
| 1235.1.358 Boehringer Ingelheim Investigational Site | Salt Lake City | Utah | — | — |
| 1235.1.464 Boehringer Ingelheim Investigational Site | Salt Lake City | Utah | — | — |
| 1235.1.437 Boehringer Ingelheim Investigational Site | Burke | Virginia | — | — |
| 1235.1.447 Boehringer Ingelheim Investigational Site | Fredericksburg | Virginia | — | — |
| 1235.1.371 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00281580, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 27, 2014 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00281580 live on ClinicalTrials.gov.